How Liver Disease Starves Your Joints of Selenium and Drives Osteoarthritis
A new liver-cartilage axis shows hepatic dysfunction cuts selenium supply to joints, accelerating cartilage aging — and supplementation reverses it.
Summary
Researchers at Seoul National University discovered that liver disease silently deprives cartilage of selenium, a critical micronutrient, by impairing the protein that normally shuttles it from liver to joints. When liver cells are stressed — whether by acute injury or fatty liver disease — they produce less selenoprotein P (SELENOP), the main selenium transporter in blood. Cartilage cells deprived of selenium then accumulate oxidative damage and undergo senescence, accelerating osteoarthritis. Nationwide cohort data confirmed that people with liver disease have significantly higher rates of osteoarthritis. Crucially, inorganic selenium supplementation bypassed the broken delivery system, restored protective selenoproteins in cartilage, and reduced joint damage in mouse models. The findings reframe osteoarthritis as a systemic metabolic disease with a clear nutritional intervention point.
Detailed Summary
Osteoarthritis affects hundreds of millions of people worldwide, yet it has long been treated as a purely mechanical, localized joint problem. This landmark study in Cell Metabolism overturns that view by identifying a systemic liver-to-cartilage communication axis centered on the micronutrient selenium — and showing that metabolic liver disease silently sabotages it.
The researchers used nationwide epidemiological cohorts in South Korea and found that individuals with liver disease carry a significantly elevated prevalence of osteoarthritis. This correlation prompted a mechanistic investigation. In multiple mouse models — including acute liver injury and metabolic dysfunction-associated steatohepatitis (MASH, the modern term for advanced fatty liver disease) — the team traced the breakdown to a single protein: selenoprotein P (SELENOP), which the liver normally secretes to transport selenium through the bloodstream to peripheral tissues, including cartilage.
Under hepatic stress, SELENOP output collapses via two convergent mechanisms: transcriptional repression (less gene expression) and translational suppression caused by ribosome collisions on selenium-rich SELENOP messenger RNA. The result is a cartilage-level selenium deficit that leaves chondrocytes unable to maintain their antioxidant selenoprotein network, pushing them into cellular senescence — a hallmark of aging tissue — and worsening joint degradation.
The most clinically exciting finding is the therapeutic bypass. Because inorganic selenium (e.g., selenite) does not depend on SELENOP for cellular uptake, supplementation restored chondrocyte selenoproteins and meaningfully reduced osteoarthritis severity in the mouse models, even in the setting of ongoing liver dysfunction.
For the growing population with metabolic liver disease — now estimated to affect 25–30% of adults globally — this research suggests that selenium status deserves monitoring and correction as part of joint-health management. Caveats include reliance on mouse models for mechanistic data and the need for clinical trials to establish safe, effective supplementation regimens in humans. Summary is based on the abstract only.
Key Findings
- Liver disease patients had significantly higher osteoarthritis prevalence in nationwide South Korean cohort data.
- Hepatic stress suppresses selenoprotein P (SELENOP) via dual transcriptional and translational mechanisms.
- Reduced SELENOP output starves cartilage of selenium, triggering chondrocyte senescence and joint damage.
- Inorganic selenium supplementation bypasses impaired SELENOP delivery and alleviates osteoarthritis in mice.
- Fatty liver disease (MASH) represents a systemic risk factor for cartilage degeneration through selenium depletion.
Methodology
The study combined nationwide epidemiological cohort analysis with murine models of acute liver injury, chronic liver damage, and MASH to establish and mechanistically dissect the liver-cartilage selenium axis. Mechanistic work included transcriptional and translational assays on SELENOP expression in hepatocytes under stress, plus selenium supplementation rescue experiments in vivo.
Study Limitations
Mechanistic findings are derived from mouse models and may not fully translate to human cartilage biology. No human supplementation trial was conducted, so optimal selenium dosing, safety margins, and efficacy in people with liver disease remain unknown. This summary is based on the abstract only; full experimental details, statistical methods, and supplementary data were not accessible.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: